NCT05854966 2024-09-19CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)Wake Forest University Health SciencesPhase 2 Withdrawn
NCT01520805 2016-12-29Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic SyndromeCornerstone PharmaceuticalsPhase 2 Withdrawn